39. 中毒性表皮壊死症
[臨床試験数:11,薬物数:18(DrugBank:8),標的遺伝子数:11,標的パスウェイ数:101

Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis", "TEN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02987257
(ClinicalTrials.gov)
April 202125/11/2016NATIENS: Optimal Management and Mechanisms of SJS/TENNATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal NecrolysesDrug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3Vanderbilt University Medical CenterUniversity of Ottawa;University of TorontoNot yet recruiting18 YearsN/AAll267Phase 3United States
2NCT03585946
(ClinicalTrials.gov)
January 1, 202114/3/2018Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisA Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis;Drug ReactionDrug: Site specific standard of care comparisonMassachusetts General HospitalNULLNot yet recruiting18 YearsN/AAll750NULL
3JPRN-jRCTs061180044
01/06/201712/03/2019Multicenter Open-trial of Steroid pulse therapy for SJS/TENMulticenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study Stevens-Johnson syndrome and Toxic epidermal necrolysis1. infusion of methylprednisolone at 500~1000 mg/d
(0.9% N/S in 3 hour) for 3 consecutive days.
2. Oral predonisolone (0.5 mg/kg/d) was initiated on the
day following the last dose of methylprednisolone, and
prednisolone was subsequently tapered within 2 weeks.
If the ocular involvement score is more than 2, dose of
oral predonisolone (1 mg/kg/d) is recommended.
Morita EishinNULLNot Recruiting>= 20age old<= 90age oldBoth20Phase 2Taiwan;Germany;Japan
4NCT02319616
(ClinicalTrials.gov)
November 201615/12/2014Topical Clobetasol for the Treatment of Toxic Epidermal NecrolysisA Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)Toxic Epidermal NecrolysisDrug: Clobetasol 0.05% ointment;Drug: PlaceboUniversity of California, DavisNULLWithdrawn7 Years85 YearsAll0Phase 1;Phase 2United States
5NCT02795143
(ClinicalTrials.gov)
November 20166/6/2016Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyEvaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot StudyToxic Epidermal NecrolysisDrug: Isotretinoin;Other: PlaceboMassachusetts General HospitalNULLRecruiting18 Years69 YearsBoth40N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02739295
(ClinicalTrials.gov)
July 20164/4/2016G-CSF in the Treatment of Toxic Epidermal NecrolysisEvaluation of G-CSF as a Treatment of Toxic Epidermal NecrolysisStevens - Johnson SyndromeDrug: recombinant granulocyte - colony stimulating factor;Drug: NaCl 0.9%University of LiegeNULLRecruiting18 YearsN/AAll10Phase 4Belgium
7NCT02126020
(ClinicalTrials.gov)
November 201427/4/2014Topical Infliximab in Autoimmune Eyes With KeratoprosthesisTopical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane PemphigoidDrug: topical infliximabJames Chodosh, MD, MPHMassachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)Withdrawn18 Years80 YearsAll0Phase 1;Phase 2United States;Canada
8NCT01696500
(ClinicalTrials.gov)
October 201220/9/2012Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.Stevens-Johnson Syndrome;Toxic Epidermal NecrolysisDrug: Intravenous immunoglobulinNihon Pharmaceutical Co., LtdNULLCompleted20 YearsN/ABoth10Phase 3Japan
9NCT01256489
(ClinicalTrials.gov)
December 201019/11/2010Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal NecrolysisStevens-Johnson Syndrome;Corneal BlindnessDrug: InfliximabMassachusetts Eye and Ear InfirmaryNULLWithdrawn18 YearsN/ABoth0Phase 1;Phase 2United States
10NCT02037347
(ClinicalTrials.gov)
October 201013/1/2014Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal NecrolysisPalifermin Treatment of Toxic Epidermal NecrolysisToxic Epidermal Necrolysis;Stevens-Johnson SyndromeDrug: PaliferminBrett KingSwedish Orphan BiovitrumTerminated18 YearsN/AAll1Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00372723
(ClinicalTrials.gov)
July 20065/9/2006Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal NecrolysisToxic Epidermal NecrolysisDrug: Remicaide (infliximab)Loyola UniversityNULLWithdrawn18 YearsN/ABoth0Phase 2United States